Funding for this research was provided by:
Received: 10 August 2020
Accepted: 2 February 2021
First Online: 11 March 2021
Ethics approval and consent to participate
: The patient interviews were approved by the New England Institutional Review Board and all interviewed patients completed an informed consent form. The ASCEND trial protocol was approved by the institutional review board or independent ethics committee at each site, the study was conducted according to the principles of the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice, and all patients provided written informed consent.
: Not applicable.
: DE is an employee of AstraZeneca and holds shares in AstraZeneca. CI, LC and OM are employees of IQVIA, which received funds from AstraZeneca to conduct the psychometric analysis of the study data. DC owns the FACIT questionnaires, and all related subscales, translations and adaptations (ExternalRef removed).